Tumor mutational burden predicts treatment response among women, not men, with melanoma
Source: Healio, April 2021
Tumor mutational burden predicted immune checkpoint inhibitor response among women, but not men, with melanoma, according to findings presented during the virtual American Association for Cancer Research Annual Meeting.
